<DOC>
	<DOCNO>NCT01512784</DOCNO>
	<brief_summary>Infection human immunodeficiency virus ( HIV ) important risk factor HPV infection development HPV-associated lesion female male anogenital tract . Data safety immunogenicity quadrivalent human papillomavirus vaccine HIV-infected population . The present study non-randomized control clinical trial primary objective determine safety ad immunogenicity quadrivalent human papillomavirus vaccine ( Gardasil® ) HIV-infected female male adolescent young adult .</brief_summary>
	<brief_title>Long Term Immunogenicity Quadrivalent Human Papillomavirus Vaccine ( Gardasil® ) HIV-infected Adolescents Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>For HIVinfected healthy subject : Subjects age 1327 year , females male Written inform consent parent guardian applicable ( age &lt; 18 year ) For HIVinfected subject : HIVpositive Asymptomatic subject ( generalize lymphadenopathy accept ) Lymphocyte CD4+ count &gt; equal 350 cells/mm3 For subject receive HAART : Good compliance therapy At least two suppressed viral load HIVRNA ( &lt; 37copies/ml9 6 month prior enrollment . For female subject ( HIVinfected healthy ) Pregnancy breastfeed Total hysterectomy . Participants undergone partial hysterectomy cervix exclude . For female male ( HIVinfected healthy ) : Prior vaccination quadrivalent HPV vaccine Gardasil study entry . History severe allergic reaction previous vaccination hypersensitivity vaccine component . Any serious chronic progressive disease ( HIV ) accord judgment investigator : Acute infection require therapy fever time enrollment Chronic autoimmune oncologic disease receive chemotherapy Concomitant therapy ( HAART ) : Chronic therapy ( 14 day consecutively ) immunosuppressive immunomodulating agent chemotherapy 6 month prior study entry . Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation prior study entry . Use investigational agent within 4 week prior study enrollment . Current drug alcohol use dependence . Documented history nonadherence antiretroviral treatment regimen within 12 month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>27 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Quadrivalent Human Papillomavirus Vaccine ( HPV ) Gardasil</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Evaluation quadrivalent HPV vaccine adolescent young adult .</keyword>
</DOC>